ASX:TLXBiotechs
Should SEC Subpoena And FDA Letter Disclosures Require Action From Telix Pharmaceuticals (ASX:TLX) Investors?
In 2025–2026, Telix Pharmaceuticals became the focus of multiple securities class action lawsuits after disclosures of an SEC subpoena and an FDA Complete Response Letter concerning its prostate cancer diagnostics and therapeutics.
The allegations center on whether Telix accurately described the progress of its pipeline and the robustness of its third-party manufacturing network, raising wider questions about disclosure practices in complex biotech supply chains.
We’ll now examine how...